clobetasol propionate .5 mg/g Aerosol, Foam, 50 g — NDC 68462-625-27 (Billing 68462-0625-27)
This is a package of 50 g of clobetasol propionate .5 mg/g Aerosol, Foam from Glenmark Pharmaceuticals Inc., USA, marketed since Sep 2019 and currently FDA-listed; retail pharmacies pay about $2.24 per g (NADAC). It is the main listing for this product, which comes in 2 package sizes.
NDC database record
One package, one record: these facts belong to NDC 68462-625-27 alone.
- Record
- FDA NDC Directory package listing · Human prescription drug
- Code segments
- 68462 labeler · 625 product · 27 package
- Package marketed since
- Sep 9, 2019
- Sample package
- No — commercial package
- Listing certified through
- Dec 31, 2027
- Billing quantity
- 50 g per package
- Barcode (UPC-A, from the NDC)
- 3 6846262527 9
- Medicaid fills, this package
- 126 prescriptions in the last four reported quarters
- FDA record last changed
- Jul 24, 2026
Other active recalls for Clobetasol Propionate (different manufacturers) — 1 · tap to view
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification
- GSN (GCN sequence number): 061865
- GCN: 97649
- GPI-14 (Medi-Span): 90550025203920
- HICL (First Databank): 009061
- AHFS class code: 84:06.08.00
- RxCUI (RxNorm): 1992273
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 8, 2026
- FDA label on DailyMed · label index refreshed Oct 8, 2026
- RxNorm (NLM RxNav) · catalog refreshed Oct 1, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Oct 8, 2026
RxNorm drug class
This medicine belongs to the Corticosteroid class.
Where does this data come from?
- RxClass (NLM) · catalog refreshed Oct 1, 2026
Clinical
- It calms inflamed, itchy skin and scalp conditions, including plaque psoriasis. The exact use depends on your product, such as shampoo for scalp psoriasis or spray for plaque psori...
- Usually only a short time, often 2 weeks and up to 4 weeks for some products. Stop when your skin is under control. If you see no improvement in 2 weeks, check back with your presc...
- Generally no. Most clobetasol skin products should not be used on the face, armpits or groin. Keep it out of your eyes and mouth, and follow your product's directions.
- Mild burning, stinging, itching or dryness where you apply it. Call your doctor if your skin thins, breaks out, looks infected or gets worse. Also call for signs of steroid effects...
Patient education
Supplement & herbal interactions
Some supplements/herbs that may interact with Clobetasol Propionate — tap one for details:
Clobetasol may be associated with lower levels of 8 nutrients — worth a chat with your pharmacist, not a cause for alarm.
Where does this data come from?
- MedlinePlus (NLM) · refreshed Oct 8, 2026
- FDA label on DailyMed · label index refreshed Oct 8, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per g | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | $2.236 | $111.82 / 50 g |
| Medicaid paysCMS SDUD · 12 mo | $2.50 | $124.97 / 50 g |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
Where does this data come from?
- CMS NADAC weekly file · file of Oct 7, 2026
- CMS ASP pricing files · refreshed Sep 20, 2026
- CMS Medicaid State Drug Utilization Data · through Q1 2026
- CMS Part D plan pricing files · refreshed Sep 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Per unit | Per pack | Marketing start | Marketing end | Status |
|---|---|---|---|---|---|---|
| 68462-0625-27 You're viewing this Main listing | 50 g in 1 CAN | $2.24 / g | $111.82 | 2019-09-09 | — | Active |
| 68462-0625-94 68462-625-94 | 100 g in 1 CAN | $1.79 / g | $178.92 | 2019-09-09 | — | Active |
You're viewing the smallest of 2 pack sizes for this product.
Per g, this pack runs about 25% above the cheapest pack (100 g, $1.79 vs $2.24 NADAC).
In Medicaid, this is the most-dispensed pack of this product — about 70% of fills over the last four reported quarters. See all packs ↓
Pack size FAQ
What quantity is in this package?
How does this package differ from NDC 68462-0625-94?
What NDC number is used to bill for this package of clobetasol propionate .5 mg/g Aerosol, Foam?
Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Clobetasol Propionate .5 mg/g 62332-0707-31 | Alembic | 1 can | $0.304 | AB1 | Availability likely | save 86% |
| Clobetasol Propionate .5 mg/g 45802-0437-32 | Padagis | 1 can | $0.405 | AB1 | Availability likely | save 82% |
| Clobetasol Propionate .5 mg/g 51672-4193-03 | Sun | 1 can | $0.405 | AB1 | Availability likely | save 82% |
| Clobetasol Propionate .5 mg/g 68462-0608-27 | Glenmark | 50 g | $0.405 | AB1 | Availability likely | save 82% |
| Tovet (emollient formulation) .5 mg/g 43538-0952-10 | Medimetriks | 1 canister | $1.789 | AB2 | Availability likely | save 20% |
| clobetasol propionate emollient formulation .5 mg/g 45802-0637-32 | Padagis | 1 can | $2.236 | AB2 | Availability likely | — |
| clobetasol propionate .5 mg/gthis 68462-0625-27 | Glenmark | 50 g | $2.236 | AB2 | Availability likely | — |
| Clobetasol Propionate .5 mg/g 63629-9460-01 | Bryant | 1 can | — | AB1 | FDA listed | — |
| Clobetasol Propionate .5 mg/g 46708-0707-31 | Alembic | 1 can | — | AB1 | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 8, 2026
- FDA Orange Book · refreshed Oct 3, 2026
- CMS NADAC weekly file · file of Oct 7, 2026
Availability & generic status
This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.
Where does this data come from?
- FDA Orange Book · refreshed Oct 3, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
🧪 Avoiding an ingredient? See Clobetasol inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII XF417D3PSL
Anhydrous citric acid is a sour, crystalline powder derived from citric acid with water removed. In medicines, it acts as a buffer to control pH, adds tartness to improve taste, and helps tablets disintegrate.
-
UNII 6LV4FOR43R
Butane is a colorless gas derived from petroleum. In medicines, it serves as a propellant in inhalers and aerosol sprays, helping deliver the active drug to the lungs or skin.
-
UNII 936JST6JCN
Cetyl alcohol is a waxy, fatty substance derived from plant or animal sources. It acts as an emulsifier and thickener in medicines, helping blend oil and water components and giving products a smooth, creamy texture.
-
UNII NMQ347994Z
Cyclomethicone is a silicone-based fluid that acts as a lubricant and solvent in medicines. It helps products flow smoothly, reduces friction between particles, and aids in even distribution of active ingredients.
-
UNII 0RE8K4LNJS
Isopropyl myristate is an oily liquid made from coconut or palm oil. It's used in medicines as an emollient and penetration enhancer to help the medicine absorb through skin or improve spreadability in topical products.
-
UNII N6K5787QVP
Light mineral oil is a clear, odorless liquid derived from petroleum. In medicines, it acts as a lubricant and emollient to help the product spread smoothly and improve texture.
-
UNII 4T6H12BN9U
Petrolatum is a purified mineral oil-based jelly derived from petroleum. In medicines, it acts as an emollient, lubricant, and moisture barrier to soften skin, reduce friction, and help prevent water loss from formulations.
-
UNII HIE492ZZ3T
Phenoxyethanol is a synthetic preservative and antimicrobial agent used to prevent bacterial and fungal growth in medicines and cosmetic products, extending shelf life and maintaining product safety.
-
UNII YRC528SWUY
A waxy emulsifier made from plant-derived fatty alcohols. It helps blend oil and water-based ingredients together and improves how the medicine spreads and absorbs.
-
UNII EE90ONI6FF
Potassium citrate is a salt derived from citric acid and potassium. In medicines, it acts as a buffer to adjust and maintain the pH balance of the product, helping keep it stable and palatable.
-
UNII T75W9911L6
A flammable gas used as a propellant in aerosol formulations. It helps dispense the medicine as a fine mist or spray when you activate the inhaler or pump.
-
UNII 6DC9Q167V3
Propylene glycol is a clear liquid derived from petroleum or vegetable sources. It acts as a solvent, humectant, and preservative in medicines, helping dissolve active ingredients and maintain product stability.
-
UNII 6W9PS8B71J
Sorbitan monolaurate is a natural oil-derived emulsifier made from sorbitol and lauric acid. It helps mix oils and water-based ingredients together in the medicine so the formula stays uniform and smooth.
-
UNII 059QF0KO0R
Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.
14 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Oct 8, 2026
- FDA openFDA NDC Directory · synced Oct 8, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from Glenmark Pharmaceuticals Inc., USA labeler code 68462
- nebivolol 5 mg Tablet NDC 68462-616-01
- nebivolol 10 mg Tablet NDC 68462-617-01
- nebivolol 20 mg Tablet NDC 68462-618-01
- Colesevelam Hydrochloride 3.75 g Powder, For Suspension NDC 68462-620-30
- Fosphenytoin sodium 50 mg/mL Injection, Solution NDC 68462-621-02
- Fosphenytoin sodium 50 mg/mL Injection, Solution NDC 68462-622-10
- azelaic acid .15 g/g Gel NDC 68462-626-52
- Pramipexole dihydrochloride .75 mg Tablet NDC 68462-627-05
- Levonorgestrel and Ethinyl Estradiol 90 ug; 20 ug Tablet NDC 68462-637-29
- Nitroglycerin .3 mg Tablet NDC 68462-638-01
- Nitroglycerin .4 mg Tablet NDC 68462-639-01
- Nitroglycerin .6 mg Tablet NDC 68462-640-01
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 8, 2026
- Drugs@FDA
Full prescribing information FDA SPL
🎯 Indications and Usage ▾
1 INDICATIONS AND USAGE Clobetasol propionate emulsion foam is indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 12 years and older. Clobetasol propionate emulsion foam is a corticosteroid indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients aged 12 years and older. ( 1 )
⏱️ Dosage and Administration ▾
2 DOSAGE AND ADMINISTRATION • Apply a thin layer of clobetasol propionate emulsion foam to the affected area(s) twice daily, morning and evening, for up to 2 consecutive weeks; therapy should be discontinued when control has been achieved. • The maximum weekly dose should not exceed 50 g or an amount greater than 21 capfuls per week. • For proper dispensing of foam, shake the can, hold it upside down, and depress the actuator. • Dispense a small amount of foam (about a capful) and gently massage the medication into the affected areas (excluding the face, groin, and axillae) until the foam is absorbed. • Clobetasol propionate emulsion foam is not for oral, ophthalmic, or intravaginal use. • Avoid contact with the eyes. • Avoid use on face, axillae, and groin, or if skin atrophy is present at the treatment site. • Wash hands after each application.
Clobetasol propionate emulsion foam is not for oral, ophthalmic, or intravaginal use. ( 2 ) • Apply clobetasol propionate emulsion foam to the affected area(s) twice daily, morning and evening, for up to 2 consecutive weeks. The maximum weekly dose should not exceed 50 g.
( 2 ) • Avoid use on face, axilla, and groin, or if skin atrophy is present at the treatment site. ( 2 )
💊 Dosage Forms and Strengths ▾
3 DOSAGE FORMS AND STRENGTHS Clobetasol Propionate Emulsion Foam, 0.05% contains 0.5 mg of clobetasol propionate, USP per gram in a white to off-white emulsion aerosol foam. Foam, 0.05%. ( 3 )
⛔ Contraindications ▾
4 CONTRAINDICATIONS None. None. ( 4 )
⚠️ Warnings and Cautions ▾
5 WARNINGS AND PRECAUTIONS • Clobetasol propionate emulsion foam has been shown to suppress the HPA axis. Systemic absorption of clobetasol propionate emulsion foam may produce reversible HPA axis suppression, Cushing’s syndrome, hyperglycemia, and unmask latent diabetes. ( 5.1 ) • Because of the potential for systemic absorption, use of topical corticosteroids may require that patients be periodically evaluated for HPA axis suppression.
( 5.1 ) • Modify use should HPA axis suppression develop. ( 5.1 ) • High potency corticosteroids, large treatment surface areas, prolonged use, use of occlusive dressings, altered skin barrier, and liver failure may predispose patients to HPA axis suppression. ( 5.1 ) • May increase the risk of cataract and glaucoma.
If visual symptoms occur, consider referral to an ophthalmologist for evaluation. ( 5.3 ) • Pediatric patients may be more susceptible to systemic toxicity when treated with topical corticosteroids. ( 5.1 , 8.4 ) • The propellant in clobetasol propionate emulsion foam is flammable.
Avoid fire, flame, or smoking during and immediately following application. ( 5.5 )
5.1Effects on Endocrine System Clobetasol propionate emulsion foam has been shown to suppress the hypothalamic-pituitary-adrenal (HPA) axis. Systemic absorption of clobetasol propionate emulsion foam has caused reversible HPA axis suppression with the potential for clinical glucocorticoid insufficiency. This may occur during treatment or upon withdrawal of the topical corticosteroid.
Use of clobetasol propionate emulsion foam for longer than 2 weeks may suppress the immune system [see Nonclinical Toxicology (13.1) ]. In a trial including 37 subjects ages 12 years and older with atopic dermatitis of at least 30% body surface area (BSA), adrenal suppression was identified in 6 out of 37 subjects (16.2%) after 2 weeks of treatment with clobetasol propionate emulsion foam [see Clinical Pharmacology (12.2 )] . Because of the potential for systemic absorption, use of clobetasol propionate emulsion foam may require that patients be periodically evaluated for HPA axis suppression.
Factors that predispose a patient using a topical corticosteroid to HPA axis suppression include the use of more potent steroids, use over large surface areas, use over prolonged periods, use under occlusion, use on an altered skin barrier, and use in patients with liver failure. An adrenocorticotrophic hormone (ACTH) stimulation test may be helpful in evaluating patients for HPA axis suppression. If HPA axis suppression is documented, an attempt should be made to gradually withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid.
Manifestations of adrenal insufficiency may require systemic corticosteroids. Recovery of HPA axis function is generally prompt and complete upon discontinuation of topical corticosteroids. Cushing’s syndrome, hyperglycemia, and unmasking of latent diabetes mellitus can also result from systemic absorption of topical corticosteroids.
Use of more than 1 corticosteroid-containing product at the same time may increase the total systemic corticosteroid exposure. Pediatric patients may be more susceptible to systemic toxicity from equivalent doses because of their larger skin surface-to-body mass ratios [see Use in Specific Populations (8.4) ].
5.2Local Adverse Reactions with Topical Corticosteroids Local adverse reactions may be more likely to occur with occlusive use, prolonged use, or use of higher potency corticosteroids. Reactions may include atrophy, striae, telangiectasias, burning, itching, irritation, dryness, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, and miliaria. Some local adverse reactions may be irreversible.
Allergic contact dermatitis to any component of topical corticosteroids is usually diagnosed by a failure to heal rather than a clinical exacerbation. Clinical diagnosis of allergic contac… [Excerpted — this section continues on DailyMed.]
🤒 Adverse Reactions ▾
6 ADVERSE REACTIONS The following adverse reactions are discussed in greater detail in other sections of the labeling: • Effects on Endocrine System [see Warnings and Precautions (5.1) ] • Ophthalmic Adverse Reactions [see Warnings and Precautions (5.3) ] • The most common adverse reactions (incidence ≥1%) are application site atrophy and application site reaction. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Glenmark Pharmaceuticals Inc., USA at 1 (888) 721-7115 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. In controlled clinical trials involving 821 subjects exposed to clobetasol propionate emulsion foam and vehicle foam, the pooled incidence of local adverse reactions in trials for atopic dermatitis and psoriasis with clobetasol propionate emulsion foam was 1.9% for application site atrophy and 1.6% for application site reaction.
Most local adverse events were rated as mild to moderate and they were not affected by age, race, or gender.
6.2Postmarketing Experience Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following adverse reactions have been identified during post-approval use of clobetasol formulations: erythema, pruritus, burning, alopecia, and dryness. The following additional local adverse reactions have been reported with topical corticosteroids: folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, irritation, striae, and miliaria.
They may occur more frequently with the use of occlusive dressings and higher potency corticosteroids, such as clobetasol propionate. Cushing’s syndrome has been reported in infants and adults as a result of prolonged use of topical clobetasol propionate formulations. Ophthalmic adverse reactions may include cataracts, glaucoma, increased intraocular pressure, and central serous chorioretinopathy.
👥 Use in Specific Populations ▾
8 USE IN SPECIFIC POPULATIONS
8.1Pregnancy Risk Summary There are no available data on clobetasol propionate emulsion foam use in pregnant women to inform of a drug associated risk for adverse developmental outcomes. Published data report a significantly increased risk of low birthweight with the use of greater than 300 grams of potent or very potent topical corticosteroid during a pregnancy. Advise pregnant women of the potential risk to a fetus and to use clobetasol propionate emulsion foam on the smallest area of skin and for the shortest duration possible ( see Data ).
In animal reproduction studies, increased malformations, such as cleft palate and skeletal abnormalities, were observed after subcutaneous administration of clobetasol propionate to pregnant mice and rabbits. No comparison of animal exposure with human exposure was computed. The background risk of major birth defects and miscarriage for the indicated population is unknown.
All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Human Data Multiple observational studies found no significant associations between maternal use of topical corticosteroids of any potency and congenital malformations, preterm delivery, or fetal mortality.
However, when the dispensed amount of potent or very potent topical corticosteroid exceeded 300 g during the entire pregnancy, use was associated with an increase in low birth weight infants (adjusted RR, 7.74 [95% CI, 1.49 to 40.11]). In addition, a small cohort study, in which 28 sub-Saharan women using potent topical corticosteroids (27/28 used clobetasol propionate 0.05%) for skin lightening during pregnancy, noted a higher incidence of low birth weight infants in the exposed group. The majority of exposed subjects treated large areas of the body (a mean quantity of 60 g/month [range, 12 to 170 g]) over long periods of time.
Animal Data Embryofetal development studies conducted with clobetasol propionate in mice using the subcutaneous route resulted in fetotoxicity at the highest dose tested (1 mg/kg) and malformations at all dose levels tested down to 0.03 mg/kg. Malformations seen included cleft palate and skeletal abnormalities. In an embryofetal development study in rabbits, subcutaneous administration of clobetasol propionate resulted in malformations at doses of 0.003 and 0.01 mg/kg.
Malformations seen included cleft palate, cranioschisis, and other skeletal abnormalities.
8.2Lactation Risk Summary There is no information regarding the presence of clobetasol propionate in breast milk or its effects on the breastfed infant or on milk production. Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of clobetasol propionate could result in sufficient systemic absorption to produce detectable quantities in human milk.
The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for clobetasol propionate emulsion foam and any potential adverse effects on the breastfed infant from clobetasol propionate emulsion foam or from the underlying maternal condition. Clinical Considerations To minimize potential exposure to the breastfed infant via breast milk, use clobetasol propionate emulsion foam on the smallest area of skin and for the shortest duration possible while breastfeeding. Advise breastfeeding women not to apply clobetasol propionate emulsion foam directly to the nipple and areola to avoid direct infant exposure.
8.4Pediatric Use Use in pediatric patients younger than 12 years is not recommended because of the risk of HPA axis suppression. After two weeks of twice-daily treatment with clo… [Excerpted — this section continues on DailyMed.]
🤰 Pregnancy ▾
8.1Pregnancy Risk Summary There are no available data on clobetasol propionate emulsion foam use in pregnant women to inform of a drug associated risk for adverse developmental outcomes. Published data report a significantly increased risk of low birthweight with the use of greater than 300 grams of potent or very potent topical corticosteroid during a pregnancy. Advise pregnant women of the potential risk to a fetus and to use clobetasol propionate emulsion foam on the smallest area of skin and for the shortest duration possible ( see Data ).
In animal reproduction studies, increased malformations, such as cleft palate and skeletal abnormalities, were observed after subcutaneous administration of clobetasol propionate to pregnant mice and rabbits. No comparison of animal exposure with human exposure was computed. The background risk of major birth defects and miscarriage for the indicated population is unknown.
All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Human Data Multiple observational studies found no significant associations between maternal use of topical corticosteroids of any potency and congenital malformations, preterm delivery, or fetal mortality.
However, when the dispensed amount of potent or very potent topical corticosteroid exceeded 300 g during the entire pregnancy, use was associated with an increase in low birth weight infants (adjusted RR, 7.74 [95% CI, 1.49 to 40.11]). In addition, a small cohort study, in which 28 sub-Saharan women using potent topical corticosteroids (27/28 used clobetasol propionate 0.05%) for skin lightening during pregnancy, noted a higher incidence of low birth weight infants in the exposed group. The majority of exposed subjects treated large areas of the body (a mean quantity of 60 g/month [range, 12 to 170 g]) over long periods of time.
Animal Data Embryofetal development studies conducted with clobetasol propionate in mice using the subcutaneous route resulted in fetotoxicity at the highest dose tested (1 mg/kg) and malformations at all dose levels tested down to 0.03 mg/kg. Malformations seen included cleft palate and skeletal abnormalities. In an embryofetal development study in rabbits, subcutaneous administration of clobetasol propionate resulted in malformations at doses of 0.003 and 0.01 mg/kg.
Malformations seen included cleft palate, cranioschisis, and other skeletal abnormalities.
🧒 Pediatric Use ▾
8.4Pediatric Use Use in pediatric patients younger than 12 years is not recommended because of the risk of HPA axis suppression. After two weeks of twice-daily treatment with clobetasol propionate emulsion foam, 7 of 15 subjects (47%) aged 6 to 11 years demonstrated HPA axis suppression. The laboratory suppression was transient; in all subjects serum cortisol levels returned to normal when tested 4 weeks post-treatment.
In 92 subjects aged 12 to 17 years, safety was similar to that observed in the adult population. Based on these data, no adjustment of dosage of clobetasol propionate emulsion foam in adolescent patients aged 12 to 17 years is warranted [see Warnings and Precautions (5.1) ]. Because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of HPA axis suppression and Cushing’s syndrome when they are treated with topical corticosteroids.
They are therefore also at greater risk of adrenal insufficiency during and/or after withdrawal of treatment. HPA axis suppression, Cushing’s syndrome, linear growth retardation, delayed weight gain, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include low plasma cortisol levels and an absence of response to ACTH stimulation.
Manifestations of intracranial hypertension include bulging fontanelles (in infants), headaches, and bilateral papilledema. Administration of topical corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children.
Adverse effects, including striae, have been reported with inappropriate use of topical corticosteroids in infants and children.
🧓 Geriatric Use ▾
8.5Geriatric Use A limited number of subjects aged 65 years or older have been treated with clobetasol propionate emulsion foam (n = 58) in U.S. clinical trials. While the number of subjects is too small to permit separate analysis of efficacy and safety, the adverse reactions reported in this population were similar to those reported by younger subjects. Based on available data, no adjustment of dosage of clobetasol propionate emulsion foam in geriatric patients is warranted.
🆘 Overdosage ▾
10 OVERDOSAGE Topically applied clobetasol propionate emulsion foam can be absorbed in sufficient amounts to produce systemic effects.
🧬 Clinical Pharmacology ▾
12 CLINICAL PHARMACOLOGY
12.1Mechanism of Action Corticosteroids play a role in cellular signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action in corticosteroid-responsive dermatoses is unknown.
12.2Pharmacodynamics In a trial evaluating the potential for HPA axis suppression using the cosyntropin stimulation test, clobetasol propionate emulsion foam demonstrated reversible adrenal suppression after two weeks of twice-daily use in subjects with atopic dermatitis of at least 30% body surface area (BSA). The proportion of subjects aged 12 years and older demonstrating HPA axis suppression was 16.2% (6 out of 37). In this trial HPA axis suppression was defined as serum cortisol level ≤18 mcg/dL 30 minutes post cosyntropin stimulation.
The laboratory suppression was transient; in all subjects serum cortisol levels returned to normal when tested 4 weeks post treatment [see Warnings and Precautions (5.1) , Use in Specific Populations (8.4)].
12.3Pharmacokinetics Topical corticosteroids can be absorbed from intact healthy skin. The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the product formulation and the integrity of the epidermal barrier. Occlusion, inflammation, and/or other disease processes in the skin may increase percutaneous absorption.
The use of pharmacodynamic endpoints for assessing the systemic exposure of topical corticosteroids may be necessary due to the fact that circulating levels are often below the level of detection. Once absorbed through the skin, topical corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some corticosteroids and their metabolites are also excreted in the bile.
Following twice-daily application of clobetasol propionate emulsion foam for one week to 32 adult subjects with mild to moderate plaque-type psoriasis, mean peak plasma concentrations (±SD) of 59 ± 36 pg/mL of clobetasol were observed at around 5 hours post dose on Day 8.
🧬 Mechanism of Action ▾
12.1Mechanism of Action Corticosteroids play a role in cellular signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action in corticosteroid-responsive dermatoses is unknown.
📦 How Supplied / Storage and Handling ▾
16 HOW SUPPLIED/STORAGE AND HANDLING
16.1How Supplied Clobetasol Propionate Emulsion Foam, 0.05% contains 0.5 mg of clobetasol propionate, USP per gram. The white to off-white emulsion aerosol foam is available as follows • 50 g aluminum can NDC 68462-625-27 • 100 g aluminum can NDC 68462-625-94
16.2Storage and Handling Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. FLAMMABLE. AVOID FIRE, FLAME OR SMOKING DURING AND IMMEDIATELY FOLLOWING APPLICATION. Contents under pressure. Do not puncture or incinerate. Do not expose to heat or store at temperatures above 120°F (49°C). Keep out of reach of children.
📋 Description ▾
11 DESCRIPTION Clobetasol Propionate Emulsion Foam, 0.05% is a white to off-white emulsion aerosol foam containing the active ingredient clobetasol propionate, USP, a synthetic corticosteroid for topical dermatologic use. Clobetasol, an analog of prednisolone, has a high degree of glucocorticoid activity and a slight degree of mineralocorticoid activity. Clobetasol propionate, USP is 21-chloro-9-fluoro-11β,17-dihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17-propionate, with the empirical formula C 25 H 32 ClFO 5 , and a molecular weight of 467 g/mol.
The following is the chemical structure: Clobetasol Propionate, USP Clobetasol propionate, USP is a white to almost white crystalline powder, practically insoluble in water, slightly soluble in benzene and diethyl ether; sparingly soluble in ethanol; freely soluble in acetone, in dimethylsulfoxide, in chloroform, in methanol and in dioxane. Each gram of Clobetasol Propionate Emulsion Foam, 0.05% contains 0.5 mg clobetasol propionate, USP. The foam also contains anhydrous citric acid, cetyl alcohol, cyclomethicone, isopropyl myristate, light mineral oil, polyoxyl-20 cetostearyl ether, potassium citrate, propylene glycol, purified water, sorbitan monolaurate, white petrolatum, and phenoxyethanol as a preservative.
Clobetasol Propionate Emulsion Foam is dispensed from an aluminum can pressurized with a hydrocarbon (propane/butane) propellant. structure
💬 Information for Patients ▾
17 PATIENT COUNSELING INFORMATION See FDA-Approved Patient Labeling (Patient Information) Effects on Endocrine System Clobetasol propionate emulsion foam may cause HPA axis suppression. Advise patients that use of topical corticosteroids, including clobetasol propionate emulsion foam, may require periodic evaluation for HPA axis suppression. Topical corticosteroids may have other endocrine effects.
Concomitant use of multiple corticosteroid-containing products may increase the total systemic exposure to topical corticosteroids. Patients should inform their physician(s) that they are using clobetasol propionate emulsion foam if surgery is contemplated [see Warnings and Precautions (5.1) ]. Ophthalmic Adverse Reactions Advise patients to report any visual symptoms to their healthcare providers [see Warnings and Precautions (5.3) ] .
Local Adverse Reactions Report any signs of local adverse reactions to the physician. Advise patients that local reactions and skin atrophy are more likely to occur with occlusive use or prolonged use [see Warnings and Precautions (5.2) ] . Pregnancy Advise a pregnant woman that use of clobetasol propionate emulsion foam may cause fetal harm and to use clobetasol propionate emulsion foam on the smallest area of skin and for the shortest duration possible [see Use in Specific Populations (8.1) ].
Lactation Advise a woman to use clobetasol propionate emulsion foam on the smallest area of skin and for the shortest duration possible while breastfeeding. Advise breastfeeding women not to apply clobetasol propionate emulsion foam directly to the nipple and areola to avoid direct infant exposure [see Use in Specific Populations (8.2) ]. Important Administration Instructions Patients using topical corticosteroids should receive the following information and instructions: • This medication is to be used as directed by the physician.
It is for external use only. Unless directed by the prescriber, it should not be used on the face or in skin-fold areas, such as the underarms or groin. Avoid contact with the eyes or other mucous membranes.
Wash hands after use. • As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, contact the physician. • Do not use for more than 50 grams per week of clobetasol propionate emulsion foam, or an amount greater than 21 capfuls per week [see Dosage and Administration ( 2 )] . • This medication is flammable; avoid heat, flame, or smoking when applying this product. For additional information, call Glenmark Pharmaceuticals Inc., USA at 1 (888) 721-7115.
Distributed by: Glenmark Pharmaceuticals Inc., USA Elmwood Park, NJ 07407 Questions? 1 (888) 721-7115 www.glenmarkpharma-us.com August 2025 logo
🧬 Pharmacokinetics ▾
12.3Pharmacokinetics Topical corticosteroids can be absorbed from intact healthy skin. The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the product formulation and the integrity of the epidermal barrier. Occlusion, inflammation, and/or other disease processes in the skin may increase percutaneous absorption.
The use of pharmacodynamic endpoints for assessing the systemic exposure of topical corticosteroids may be necessary due to the fact that circulating levels are often below the level of detection. Once absorbed through the skin, topical corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some corticosteroids and their metabolites are also excreted in the bile.
Following twice-daily application of clobetasol propionate emulsion foam for one week to 32 adult subjects with mild to moderate plaque-type psoriasis, mean peak plasma concentrations (±SD) of 59 ± 36 pg/mL of clobetasol were observed at around 5 hours post dose on Day 8.
🧬 Pharmacodynamics ▾
12.2Pharmacodynamics In a trial evaluating the potential for HPA axis suppression using the cosyntropin stimulation test, clobetasol propionate emulsion foam demonstrated reversible adrenal suppression after two weeks of twice-daily use in subjects with atopic dermatitis of at least 30% body surface area (BSA). The proportion of subjects aged 12 years and older demonstrating HPA axis suppression was 16.2% (6 out of 37). In this trial HPA axis suppression was defined as serum cortisol level ≤18 mcg/dL 30 minutes post cosyntropin stimulation.
The laboratory suppression was transient; in all subjects serum cortisol levels returned to normal when tested 4 weeks post treatment [see Warnings and Precautions (5.1) , Use in Specific Populations (8.4)].
🔬 Clinical Studies ▾
14 CLINICAL STUDIES In a randomized trial of subjects 12 years and older with moderate to severe atopic dermatitis, 251 subjects were treated with clobetasol propionate emulsion foam and 126 subjects were treated with vehicle foam. Subjects were treated twice daily for 2 weeks. At the end of treatment, 131 of 251 subjects (52%) treated with clobetasol propionate emulsion foam compared with 18 of 126 subjects (14%) treated with vehicle foam achieved treatment success.
Treatment success was defined by an Investigator’s Static Global Assessment (ISGA) score of clear (0) or almost clear (1) with at least 2 grades improvement from baseline, and scores of absent or minimal (0 or 1) for erythema and induration/papulation. In an additional randomized trial of subjects 12 years and older with mild to moderate plaque-type psoriasis, 253 subjects were treated with clobetasol propionate emulsion foam and 123 subjects were treated with vehicle foam. Subjects were treated twice daily for 2 weeks.
At the end of treatment, 41 of 253 subjects (16%) treated with clobetasol propionate emulsion foam compared with 5 of 123 subjects (4%) treated with vehicle foam achieved treatment success. Treatment success was defined by an ISGA score of clear (0) or almost clear (1) with at least 2 grades improvement from baseline, scores of none or faint/minimal (0 or 1) for erythema and scaling, and a score of none (0) for plaque thickness.
🧪 Nonclinical Toxicology ▾
13 NONCLINICAL TOXICOLOGY
13.1Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term animal studies have not been performed to evaluate the carcinogenic potential of clobetasol propionate emulsion foam or clobetasol propionate. In a 90-day repeat-dose toxicity study in rats, topical administration of clobetasol propionate emulsion foam at dose concentrations from 0.001% to 0.1% or from 0.03 to 0.3 mg/kg/day of clobetasol propionate resulted in a toxicity profile consistent with long term exposure to corticosteroids including adrenal atrophy, histopathological changes in several organ systems indicative of severe immune suppression and opportunistic fungal and bacterial infections.
A no observable adverse effect level could not be determined in this study. Although the clinical relevance of the findings in animals to humans is not clear, sustained glucocorticoid-related immune suppression may increase the risk of infection and possibly the risk for carcinogenesis. Clobetasol propionate was non-mutagenic in the Ames test, the mouse lymphoma test, the Saccharomyces cerevisiae gene conversion assay, and the E. coli B WP2 fluctuation test.
In the in vivo mouse micronucleus test, a positive finding was observed at 24 hours, but not at 48 hours, following oral administration at a dose of 2,000 mg/kg. Studies in the rat following subcutaneous administration of clobetasol propionate at dosage levels up to 0.05 mg/kg per day revealed that the females exhibited an increase in the number of resorbed embryos and a decrease in the number of living fetuses at the highest dose.
📄 Carcinogenesis, Mutagenesis, Impairment of Fertility ▾
13.1Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term animal studies have not been performed to evaluate the carcinogenic potential of clobetasol propionate emulsion foam or clobetasol propionate. In a 90-day repeat-dose toxicity study in rats, topical administration of clobetasol propionate emulsion foam at dose concentrations from 0.001% to 0.1% or from 0.03 to 0.3 mg/kg/day of clobetasol propionate resulted in a toxicity profile consistent with long term exposure to corticosteroids including adrenal atrophy, histopathological changes in several organ systems indicative of severe immune suppression and opportunistic fungal and bacterial infections.
A no observable adverse effect level could not be determined in this study. Although the clinical relevance of the findings in animals to humans is not clear, sustained glucocorticoid-related immune suppression may increase the risk of infection and possibly the risk for carcinogenesis. Clobetasol propionate was non-mutagenic in the Ames test, the mouse lymphoma test, the Saccharomyces cerevisiae gene conversion assay, and the E. coli B WP2 fluctuation test.
In the in vivo mouse micronucleus test, a positive finding was observed at 24 hours, but not at 48 hours, following oral administration at a dose of 2,000 mg/kg. Studies in the rat following subcutaneous administration of clobetasol propionate at dosage levels up to 0.05 mg/kg per day revealed that the females exhibited an increase in the number of resorbed embryos and a decrease in the number of living fetuses at the highest dose.
📄 Patient Package Insert ▾
PATIENT INFORMATION Clobetasol Propionate (kloe bay’ ta sol proe’ pee oh nate) Foam Important: For skin use only. Do not get clobetasol propionate emulsion foam in your eyes, mouth, or vagina. What is clobetasol propionate emulsion foam?
Clobetasol propionate emulsion foam is a prescription corticosteroid medicine used on the skin (topical) to treat people 12 years of age and older with certain skin conditions that cause red, flaky, and itchy skin. Clobetasol propionate emulsion foam is not recommended for use in children under 12 years of age. Clobetasol propionate emulsion foam should not be used: • on your face, underarms, or groin area • if you have skin thinning (atrophy) at the treatment area You should not use clobetasol propionate emulsion foam for longer than 2 weeks in a row.
You should not use more than 50 grams or 21 capfuls of clobetasol propionate emulsion foam in 1 week. Before using clobetasol propionate emulsion foam, tell your healthcare provider about all of your medical conditions, including if you: • have had irritation or other skin reaction to a steroid medicine in the past. • have a skin infection. You may need medicine to treat the skin infection before using clobetasol propionate emulsion foam. • have diabetes. • have adrenal gland problems. • have liver problems. • plan to have surgery. • are pregnant or plan to become pregnant.
It is not known if clobetasol propionate emulsion foam will harm your unborn baby. If you use clobetasol propionate emulsion foam during pregnancy, use clobetasol propionate emulsion foam on the smallest area of skin and for the shortest time needed. • are breastfeeding or plan to breastfeed. It is not known if clobetasol propionate passes into your breast milk.
If you use clobetasol propionate emulsion foam while breastfeeding, use clobetasol propionate emulsion foam on the smallest area of skin and for the shortest time needed. Do not apply clobetasol propionate emulsion foam directly to the nipple and areola to avoid getting clobetasol propionate emulsion foam into your baby’s mouth. Tell your healthcare provider about all the medicine you take including prescription and over-the‑counter medicines, vitamins, and herbal supplements.
Do not use other products containing a corticosteroid medicine during treatment with clobetasol propionate emulsion foam without talking to your healthcare provider first. How should I use clobetasol propionate emulsion foam? See the“Instructions for Use” for detailed information about the right way to apply clobetasol propionate emulsion foam . • Use clobetasol propionate emulsion foam exactly as your healthcare provider tells you to use it. • Apply a thin layer of clobetasol propionate emulsion foam to the affected area 2 times each day, 1 time in the morning and 1 time at night, or as directed by your healthcare provider. • Do not bandage, wrap or cover your treated area unless your healthcare provider tells you to. • Talk to your healthcare provider if your skin does not improve after 2 weeks of treatment with clobetasol propionate emulsion foam. • Wash your hands after using clobetasol propionate emulsion foam.
What should I avoid while using clobetasol propionate emulsion foam? Clobetasol propionate emulsion foam is flammable . Avoid heat, flame, or smoking during and right after you apply clobetasol propionate emulsion foam to your skin.
What are the possible side effects of clobetasol propionate emulsion foam? Clobetasol propionate emulsion foam may cause serious side effects, including: • Clobetasol propionate emulsion foam can pass through your skin. Too much clobetasol propionate emulsion foam passing through your skin can cause adrenal glands to stop working. • Cushing’s syndrome, a condition that happens when the body is exposed to too much of the hormone cortisol. • High blood sugar (hyperglycemia) • Vision problems.
Clobetasol propionate emulsion foam may increase your chance of developing vision problems such as cataract(s) and g… [Excerpted — this section continues on DailyMed.]
📖 Instructions for Use ▾
INSTRUCTIONS FOR USE Clobetasol Propionate (kloe bay’ ta sol proe’ pee oh nate) Foam Important information: Clobetasol propionate emulsion foam is for use on the skin only. Do not get clobetasol propionate emulsion foam in your eyes, mouth, or vagina; if contact happens, rinse well with water. How to apply clobetasol propionate emulsion foam Figure A Step 1 : Before applying clobetasol propionate emulsion foam for the first time, break the tiny plastic piece at the base of the can's rim by gently pushing back (away from the piece) on the nozzle.
(See Figure A). Figure B Step 2 : Shake the can of clobetasol propionate emulsion foam before use. (See Figure B).
Figure C Step 3 : Turn the can of clobetasol propionate emulsion foam upside down and press the nozzle. See Figure C. Figure D Step 4 : Press down on the actuator to dispense a small amount of clobetasol propionate emulsion foam into the palm of your hand.
(See Figure D). Figure E Step 5 : Apply a thin layer of clobetasol propionate emulsion foam to cover the affected area. Gently rub the foam into the affected area until the foam disappears.
(See Figure E). Step 6 : Wash your hands after applying clobetasol propionate emulsion foam. • Throw away any of the unused medicine that you dispensed out of the can. This Instructions for Use has been approved by the U.S.
Food and Drug Administration. Distributed by: Glenmark Pharmaceuticals Inc., USA Elmwood Park, NJ 07407 Questions? 1 (888) 721-7115 www.glenmarkpharma-us.com August 2025 figure1 figure2 figure3 figure4 figure5 logo2
📄 Package Label / Principal Display Panel ▾
Package/Label Display Panel carton